Qube Research & Technologies LTD Bei Gene, Ltd. Transaction History

Qube Research & Technologies LTD

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$141.8 - $181.47 $264,598 - $338,623	-1,866 Reduced 42.42%	2,533 $396,000
Q4 2023 Feb 13, 2024	BUY	$158.67 - $201.58 $654,672 - $831,719	4,126 Added 1511.36%	4,399 $793,000
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $4.12 Million - $5.16 Million	-22,931 Reduced 98.82%	273 $49,000
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $1.78 Million - $2.66 Million	9,989 Added 75.59%	23,204 $4.14 Million
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $2.85 Million - $3.63 Million	13,215 New	13,215 $2.85 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $4.19 Million - $7.47 Million	34,589 New	34,589 $5.6 Million
Q4 2021 Feb 01, 2022	SELL	$248.56 - $389.34 $1.58 Million - $2.48 Million	-6,375 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$249.6 - $403.14 $2.66 Million - $4.3 Million	-10,656 Reduced 62.57%	6,375 $2.31 Million
Q2 2021 Aug 13, 2021	BUY	$292.75 - $367.01 $4.99 Million - $6.25 Million	17,031 New	17,031 $5.85 Million
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $722,956 - $1.14 Million	-5,835 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $1.11 Million - $1.58 Million	-9,150 Reduced 61.06%	5,835 $718,000
Q4 2019 Feb 13, 2020	BUY	$115.78 - $208.34 $1.73 Million - $3.12 Million	14,985 New	14,985 $2.48 Million
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $712,356 - $880,614	-5,800 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $620,658 - $1.02 Million	5,800 New	5,800 $814,000

251

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.